Oral osmotic device with hydrogel driving member

Claim 2

An osmotic device for the controlled delivery of a beneficial agent to an oral cavity of an animal over an extended delivery period, the device having a size and shape suitable for comfortably retaining the device in the oral cavity for the extended delivery period, the device including a wall surrounding and forming a compartment containing (i) a layer of a dose of the beneficial agent and a gelling agent, the beneficial agent being insoluble to very soluble in an exterior aqueous fluid present in the oral cavity, and (ii) a layer of a hydrophilic polymer, and a passageway in the semipermeable wall communicating with the layer of beneficial agent in the compartment and with the exterior of the device, the wall being formed of a semipermeable material which is (i) permeable to the passage of the aqueous fluid and (ii) substantially impermeable to the passage of the hydrophilic polymer; the device further comprising a mechanism for signaling the animal, the mechanism including a contrast in the colors of the beneficial agent layer and the hydrophilic polymer layer, the semipermeable wall being sufficiently translucent to permit visual inspection of the beneficial agent present in the compartment, and having at least one mark indicating when a predetermined percentage of the drug dose has been delivered into the oral cavity by comparing the location of the interface with the mark.

Claim 3

The osmotic device for the controlled delivery of the beneficial agent according to claim 1, wherein the mechanism comprises means for displaying the amount of beneficial agent present in the device.

Claim 4

The osmotic device for the controlled delivery of the beneficial agent according to claim 1, wherein the semipermeable wall is sufficiently translucent to permit visual inspection of the beneficial agent present in the compartment during substantially all of the extended delivery period.

Claim 5

The osmotic device for the controlled delivery of the beneficial agent according to claim 1, wherein the semipermeable wall is sufficiently translucent to permit visual inspection of the beneficial agent present in the compartment during at least a portion of the extended delivery period.

Claim 6

The osmotic device for the controlled delivery of the beneficial agent according to claim 4, wherein the semipermeable wall has an overcoating containing beneficial agent.

Claim 7

The osmotic device for the controlled delivery of the beneficial agent according to claim 1, wherein the device has a smooth oval shape with an aspect ratio in the range of about 1.2:1 to about 3:1, a height of about 0.5 to about 10 mm, and a volume of less than about 2 cm 3 .

Claim 8

The osmotic device for the controlled delivery of the beneficial agent according to claim 1, wherein the beneficial agent is poorly soluble in the aqueous fluid and the layer of beneficial agent contains an osmagent.

Claim 9

The osmotic device for the controlled delivery of agent according to claim 1, wherein the gelling agent provides sufficient strength to the layer containing the beneficial agent to substantially prevent the wall from collapsing under conditions of use in the oral cavity.

Claim 10

The osmotic device for the controlled delivery of the beneficial agent according to claim 1, wherein the gelling agent is selected from the consisting of acacia, agar-agar, calcium carrageenan, alginic acid, algin, agarose powder, collagen, colloidal magnesium silicate, colloidal silicon dioxide, cross-linked polyacrylic acid, polyvinyl pyrrolidone, sodium carboxy methyl cellulose, hydroxy ethyl cellulose, hydroxy propyl cellulose, hydroxy propyl methyl cellulose, polyethylene oxide, pectin, gelatin and calcium silicate.

Claim 11

The osmotic device for the controlled delivery of the beneficial agent according to claim 9, wherein the gelling agent is selected from the group consisting of polyethylene oxide and hydroxy propyl methyl cellulose.

Claim 12

The osmotic device for the controlled delivery of the beneficial agent according to claim 1, wherein the wall contains a translucent cellulose polymer.

Claim 13

The osmotic device for the controlled delivery of the beneficial agent according to claim 1, wherein the beneficial agent is a member selected from the group consisting of antifungal agents, antiviral agents, antimicrobial agents, antibiotics, non-steroidal anti-inflammatory agents, anti-dental caries agents, saliva-enhancing agents, smoking cessation agents, oral ulcer healing agents and breath fresheners.

Claim 14

The osmotic device for the controlled delivery of the beneficial agent according to claim 1, wherein the hydrophilic polymer is a cross-linked hydrogel.

Claim 15

An osmotic device for the controlled delivery of a beneficial drug to an oral cavity of a human over an extended delivery period, the device having a size and shape suitable for comfortably retaining the device in the oral cavity for the extended delivery period, the device including a shaped wall surrounding and forming a compartment containing (i) a layer comprising a dose of a drug and a gelling agent, the drug being soluble to very soluble in an exterior fluid present in the oral cavity and exhibiting an osmotic pressure gradient across the wall against the exterior fluid, and (ii) a layer of an expendable hydrophilic polymer in contact with the drug layer, which hydrophilic polymer can expand from a rested to an expanded state in the presence of exterior fluid imbibed into the compartment, and a passageway in the wall communicating with the exterior of the device and the drug for delivering the drug formulation from the device at a controlled rate over an extended delivery period, the wall being formed of a semipermeable material which is (i) permeable to the passage of the exterior fluid and (ii) substantially impermeable to the passage of the hydrophilic polymer; the device further comprising a mechanism for signaling the animal, the mechanism including a contrast between the color of the drug layer and the color of the hydrophilic polymer layer, the semipermeable wall being sufficiently translucent to permit visual inspection of the drug present in the compartment, and having at least one mark indicating when a predetermined percentage of the drug dose has been delivered into the oral cavity by comparing the location of the interface with the mark.

Claim 16

An osmotic device for the controlled delivery of a beneficial drug to an oral cavity of a human over an extended delivery period, the device having a size and shape suitable for comfortably retaining the device in the oral cavity for the extended delivery period, the device including a shaped wall surrounding and forming a compartment containing (i) a layer comprising a dose of a drug and a gelling agent, the drug being soluble to very soluble in an exterior fluid present in the oral cavity and exhibiting an osmotic pressure gradient across the wall against the exterior fluid, and (ii) a layer of an expendable hydrophilic polymer in contact with the drug layer, which hydrophilic polymer can expand from a rested to an expanded state in the presence of exterior fluid imbibed into the compartment, and a passageway in the wall communicating with the exterior of the device and the drug for delivering the drug formulation from the device at a controlled rate over an extended delivery period, the wall being formed of a semipermeable material which is (i) permeable to the passage of the exterior fluid and (ii) substantially impermeable to the passage of the hydrophilic polymer; the device further comprising a mechanism for signaling the animal, the mechanism including a contrast between the color of the drug layer and the color of the hydrophilic polymer layer, the semipermeable wall being sufficiently translucent to permit visual inspection of the drug present in the compartment, and having at least one mark indicating when a predetermined percentage of the drug dose has been delivered into the oral cavity by comparing the location of the interface with the mark.

Claim 17

The osmotic device for the controlled delivery of the beneficial agent according to claim 14, wherein the mechanism comprises means for displaying the amount of drug present in the device.

Claim 18

The osmotic device for the controlled delivery of the beneficial agent according to claim 14, wherein the semipermeable wall is sufficiently translucent to permit visual inspection of the beneficial agent present in the compartment during substantially all of the extended delivery period.

Claim 19

The osmotic device for the controlled delivery of the beneficial agent according to claim 14, wherein the semipermeable wall has an overcoating containing drug.

Claim 20

The osmotic device for the controlled delivery of the beneficial agent according to claim 17, wherein the semipermeable wall is sufficiently translucent to permit visual inspection of the beneficial agent present in the compartment after the overcoating is removed.

Claim 21

The osmotic device for the controlled delivery of the beneficial agent according to claim 14, wherein the device has a smooth oval shape with an aspect ratio in the range of about 1.2:1 to about 3:1, a height of about 0.5 to about 10 mm, and a volume of less than about 2 cm 3 .

Claim 22

The osmotic device for the controlled delivery of the beneficial drug according to claim 14, wherein the device when in operation in the oral cavity imbibes fluid through the wall into the compartment, thereby (1) producing a solution of drug, and (2) causing the hydrophilic polymer to absorb the imbibed fluid and expand, whereby through the combined operation of (1) and (2) the solution is delivered through the passageway from the compartment into the oral cavity over time.

Claim 23

The osmotic device for the controlled delivery of the drug according to claim 14, wherein the drug is poorly soluble in the fluid and the drug layer contains an osmagent that is soluble in the fluid and exhibits an osmotic pressure gradient across the semipermeable wall against the exterior fluid.

Claim 24

The osmotic device for the controlled delivery of the drug formulation according to claim 14, wherein the gelling agent provides sufficient strength to the layer containing the beneficial agent to substantially prevent the wall from collapsing under conditions of use in the oral cavity.

Claim 25

The osmotic device for the controlled delivery of the drug formulation according to claim 22, wherein the gelling agent is selected from the group consisting of acacia, agar-agar, calcium carrageenan, alginic acid, algin, agarose powder, collagen, colloidal magnesium silicate, colloidal silicon dioxide, carboxy methyl cellulose, cross-linked polyacrylic acid, polyvinyl pyrrolidone, hydroxy ethyl cellulose, hydroxy propyl cellulose, hydroxy propyl methyl cellulose, polyethylene oxide, pectin, gelatin and calcium silicate.

Claim 26

The osmotic device for the controlled delivery of the drug formulation according to claim 23, wherein the gelling agent is selected from the group consisting of polyethylene oxide and hydroxy propyl methyl cellulose.

Claim 27

The osmotic device for delivering the drug according to claim 14, wherein the hydrophilic polymer is a cross-linked hydrogel.

Claim 28

The osmotic device of claim 1 or 14, wherein the device has an aspect ratio of about 1.3:1 to 2:1.

Claim 29

The osmotic device of claim 1 or 14, wherein the device has an aspect ratio of about 1.5:1 to 1.7:1.

Claim 30

The osmotic device of claim 1 or 14, wherein the device has a height of about 2 to 8 mm.

Claim 31

The osmotic device of claim 1 or 14, wherein the device has a volume of about 0.1 to 0.5 cm 3 .

Claim 32

The osmotic device of claim 1 or 14, wherein the extended delivery period is about 0.5 to 12 hours.

Claim 33

The osmotic device of claim 1 or 14, wherein the extended delivery period is about 1 to 6 hours.

Claim 34

The osmotic device for the controlled delivery of the drug according to claim 14, wherein the drug is a member selected from the group consisting of nystatin, chlorhexidene, ibuprofen, nicotine base, sodium fluoride, pilocarpine, retin A, glucocorticosteroids, testosterone, estrogen, nitroglycerin, captopril and clonidine.

Claim 35

An osmotic device for the controlled delivery of a beneficial drug formulation into a mouth of a human over an extended delivery period, the device having a size and shape suitable for comfortably retaining the device in the oral cavity for the extended delivery period, the device including a shaped wall surrounding and forming a compartment containing (i) a dose of a drug formulation which comprises a drug that is insoluble to poorly soluble in an exterior biological fluid, an osmotically effective solute that is soluble in the exterior fluid and exhibits an osmotic pressure gradient across the wall against the fluid and a gelling agent, and (ii) a layer of a hydrophilic polymer in contact with the drug formulation, which hydrophilic can absorb fluid that enters the compartment and swell, and a passageway in the semipermeable wall connecting the exterior of the device and the drug formulation for delivering the drug formulation from the device into the oral cavity at a controlled rate over the extended delivery period, the wall being permeable to the passage of the biological fluid and substantially impermeable to the passage of the hydrophilic polymer; the device further comprising a mechanism for displaying the amount of drug formulation present in the device and for signaling the human, the mechanism including a contrast between a color of the drug formulation and a color of the hydrophilic polymer layer, the semipermeable wall being sufficiently translucent to permit visual inspection of the drug formulation remaining in the compartment, the wall having at least one mark indicating when the drug dose has been completely delivered into the oral cavity by comparing the location of the interface with the mark.

Claim 36

An osmotic device for the controlled delivery of a beneficial drug formulation into a mouth of a human over an extended delivery period, the device having a size and shape suitable for comfortably retaining the device in the oral cavity for the extended delivery period, the device including a shaped wall surrounding and forming a compartment containing (i) a dose of a drug formulation which comprises a drug that is insoluble to poorly soluble in an exterior biological fluid, an osmotically effective solute that is soluble in the exterior fluid and exhibits an osmotic pressure gradient across the wall against the fluid and a gelling agent, and (ii) a layer of a hydrophilic polymer in contact with the drug formulation, which hydrophilic can absorb fluid that enters the compartment and swell, and a passageway in the semipermeable wall connecting the exterior of the device and the drug formulation for delivering the drug formulation from the device into the oral cavity at a controlled rate over the extended delivery period, the wall being permeable to the passage of the biological fluid and substantially impermeable to the passage of the hydrophilic polymer; the device further comprising a mechanism for displaying the amount of drug formulation present in the device and for signaling the human, the mechanism including a contrast between a color of the drug formulation and a color of the hydrophilic polymer layer, the semipermeable wall being sufficiently translucent to permit visual inspection of the drug formulation remaining in the compartment, the wall having at least one mark indicating when the drug dose has been completely delivered into the oral cavity by comparing the location of the interface with the mark.

Claim 37

The osmotic device for the controlled delivery of the beneficial drug formulation according to claim 33, wherein the device a height of about 3 to 5 mm, an aspect ratio of 1.5:1 to 1.7:1 and a volume of about 0.25 cm 3 .

Claim 38

The osmotic device for the controlled delivery of the beneficial drug formulation according to claim 33, wherein the extended delivery period is about 1 to 4 hours.

Claim 39

The osmotic device for the controlled delivery of the drug according to claim 33, wherein the gelling agent is selected from the group consisting of polyethylene oxide and hydroxy propyl methyl cellulose.

Claim 40

The osmotic device of claim 1 or 33, wherein the beneficial agent is nystatin.

Claim 41

The osmotic device of claim 1 or 33, wherein the beneficial agent or drug is nicotine base.

Claim 42

The osmotic device of claim 1 or 33, wherein the beneficial agent or drug is chlorhexidene.

Claim 43

The osmotic device of claim 1 or 33, wherein the beneficial agent or drug is ibuprofen.

Claim 44

The osmotic device of claim 1 or 33, wherein the beneficial agent or drug is sodium fluoride.

Claim 45

The osmotic device of claim 1 or 33, wherein the beneficial agent or drug is pilocarpine.

Claim 46

The osmotic device of claim 1 or 33, wherein the beneficial agent or drug is retin A.

Claim 47

The osmotic device of claim 1 or 33, wherein the beneficial agent or drug is a gluco-corticosteroid.

Claim 48

The osmotic device of claim 1 or 33, wherein the beneficial agent or drug is testosterone.

Claim 49

The osmotic device of claim 1 or 33, wherein the beneficial agent or drug is estrogen.

Claim 50

The osmotic device of claim 1 or 33, wherein the beneficial agent or drug is nitroglycerin.

Claim 51

The osmotic device of claim 1 or 33, wherein the beneficial agent or drug is clonidine.

Claim 52

The osmotic device of claim 1 or 33, wherein the beneficial agent or drug is captopril.